Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/18374
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAgitha, T G-
dc.date.accessioned2013-05-25T08:39:03Z-
dc.date.available2013-05-25T08:39:03Z-
dc.date.issued2013-05-
dc.identifier.issn0975-1076 (Online); 0971-7544 (Print)-
dc.identifier.urihttp://hdl.handle.net/123456789/18374-
dc.description287-293en_US
dc.description.abstractThough the Doha Declaration on TRIPS Agreement and Public Health has clarified that public health has predominance over private commercial interests, the victory of public health over trade interests appears to be momentary. The big pharmaceutical industries and the developed countries, using trade sanctions, effectively prevented developing countries from making full use of the flexibilities in the TRIPS Agreement procured by the Doha Declaration. Ultimately free trade agreements are made use of by developed countries to impose TRIPS plus obligations on developing countries. These developments once again ascertain that trade forum has its limits in protecting public health interests against trade interests.en_US
dc.language.isoen_USen_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rightsCC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceJIPR Vol.18(3) [May 2013]en_US
dc.subjectDoha Declarationen_US
dc.subjectTRIPS Agreementen_US
dc.subjectTRIPS flexibilitiesen_US
dc.subjectPublic healthen_US
dc.subjectPost Doha challengesen_US
dc.subjectCompulsory licenceen_US
dc.titleTRIPS Agreement and Public Health: The Post Doha Crisesen_US
dc.typeArticleen_US
Appears in Collections:JIPR Vol.18(3) [May 2013]

Files in This Item:
File Description SizeFormat 
JIPR 18(3) 287-293.pdf83.91 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.